Heart Failure - A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (VICTORIA)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Learn more at Clinicaltrials.org NCT 02861534

Adult Cardiology